AlzChem Group AG/€ACT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AlzChem Group AG
- Ticker
- €ACT
- Sector
- Materials
- Primary listing
- XETRA
- Employees
- 1,680
- Headquarters
- Trostberg, Germany
- Website
- www.alzchem.com
AlzChem Group AG Metrics
BasicAdvanced
€1.6B
24.12
€6.70
0.38
€2.10
1.30%
Price and volume
Market cap
€1.6B
Beta
0.38
52-week high
€165.00
52-week low
€158.80
Dividend rate
€2.10
Financial strength
Current ratio
2.704
Quick ratio
1.739
Long term debt to equity
0.302
Total debt to equity
0.332
Dividend payout ratio (TTM)
31.37%
Interest coverage (TTM)
44.77%
Profitability
EBITDA (TTM)
118.133
Gross margin (TTM)
65.63%
Net profit margin (TTM)
11.41%
Operating margin (TTM)
15.70%
Effective tax rate (TTM)
27.42%
Revenue per employee (TTM)
€350,000
Management effectiveness
Return on assets (TTM)
9.50%
Return on equity (TTM)
27.66%
Valuation
Price to earnings (TTM)
24.117
Price to revenue (TTM)
2.753
Price to book
6.06
Price to tangible book (TTM)
6.15
Price to free cash flow (TTM)
-74.021
Free cash flow yield (TTM)
-1.35%
Free cash flow per share (TTM)
-2.183
Dividend yield (TTM)
1.30%
Forward dividend yield
1.30%
Growth
Revenue change (TTM)
5.50%
Earnings per share change (TTM)
17.31%
3-year revenue growth (CAGR)
2.31%
3-year earnings per share growth (CAGR)
35.05%
3-year dividend per share growth (CAGR)
25.99%
What the Analysts think about AlzChem Group AG
Analyst ratings (Buy, Hold, Sell) for AlzChem Group AG stock.
Analyst projections of the future price of AlzChem Group AG stock.
Bulls say / Bears say
In the first half of 2026, sales rose 6% and EBITDA rose 14%, lifting the EBITDA margin to 21.2% from 19.6%. Earnings are growing faster than revenue, showing stronger profitability despite subdued industrial activity. (AlzChem Group)
Demand for AlzChem’s premium creatine brands is running ahead of available supply, and the company says global demand has tripled in two years. Its €120 million German expansion is intended to ease the shortage and support future sales growth. (NutraIngredients, AlzChem Group)
The Basics & Intermediates business remains under pressure: an analyst report cited high pricing pressure and no EBITDA from the segment in the first half. That leaves group earnings increasingly reliant on the more profitable specialty chemicals business. (EQS News)
High investment spending weakened cash generation: first-half free cash flow was negative €30.5 million, while investment more than doubled year on year to €81.2 million. Continued expansion therefore needs to translate into returns, while adding pressure to near-term cash flow. (EQS News)
The full-year guidance implies only modest second-half EBITDA growth: about €61.5 million, compared with €60 million in the same period last year. Start-up costs for the new nitroguanidine plant and the carbide-furnace work could limit the near-term earnings contribution from expansion. (EQS News, AlzChem Group)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
AlzChem Group AG Financial Performance
Revenues and expenses
AlzChem Group AG Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing AlzChem Group AG
AllUSDEURGBP
Fund name | Fund size | €ACT weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.08% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.08% |
Vanguard Germany All Cap£VGER | €258M | 0.06% |
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 0.01% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.